Patent update, page-3

Harvett, I think you will find, in time, that the Examiner has completely missed the point.

The Targeted Drug Delivery application stresses that Idronoxil needs to be dissolved in molten form within the suppository base, which has been described elsewhere as novel and inventive. Until now, prior art involved the admixing of a drug and the carrier base, which meant that the drug was in large part expelled from the body together with the suppository when it melted.

Dissolution of Idronoxil (or other drugs) within the base appears to create a "... fatty acid/isoflavonoid-type complex. In this condition, a mechanism operating at the rectal or urogenital mucosa for uptake of fatty acid chains may transport the fatty acid/isoflavonoid-type complex across the mucosa whereby the isoflavonoid or related compound is available for therapeutic effect." It is worth noting that the reformation of Idronoxil into a fatty acid/isoflavonoid complex led to Idronoxil being present in the brain in an active form; whereas oral or intravenous delivery failed in this quest.

Patent applications give a fascinating insight into things happening behind closed doors. We know that Veyonda enhances the treatment effect of radiation; and the topic of a recent application implied that Noxopharm has found an inventive connection between Veyonda and the STING process that leads to abscopal responses. And we can now see that the Targeted Drug Delivery application suggests that Veyonda may have a role in treating brain cancer.